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The rising incidence of antimicrobial resistance (AMR) makes it im-
perative to understand the underlying mechanisms. Mycobacterium
tuberculosis (Mtb) is the single leading cause of death from a bacterial
pathogen and estimated to be the leading cause of death fromAMR. A
pyrido-benzimidazole, 14, was reported to have potent bactericidal
activity against Mtb. Here, we isolated multiple Mtb clones resistant
to 14. Each had mutations in the putative DNA-binding and dimeriza-
tion domains of rv2887, a gene encoding a transcriptional repressor of
the MarR family. The mutations in Rv2887 led to markedly increased
expression of rv0560c. We characterized Rv0560c as an S-adenosyl-L-
methionine-dependent methyltransferase that N-methylates 14,
abolishing its mycobactericidal activity. An Mtb strain lacking rv0560c
became resistant to 14 by mutating decaprenylphosphoryl-β-D-ribose
2-oxidase (DprE1), an essential enzyme in arabinogalactan synthesis; 14
proved to be a nanomolar inhibitor of DprE1, andmethylation of 14 by
Rv0560c abrogated this activity. Thus, 14 joins a growing list of DprE1
inhibitors that are potently mycobactericidal. Bacterial methylation of
an antibacterial agent, 14, catalyzed by Rv0560c of Mtb, is a previously
unreported mechanism of AMR.
antimicrobial resistance | transcription factor | methyltransferase |
arabinogalactan synthesis
The World Health Organization recently announced success inmeeting the millennium development goal of reversing the rise in
worldwide incidence of tuberculosis (TB) by 2015 (1). Nonetheless,
TB mortality remains high, with 1.5 million deaths in 2013 alone, of
which 0.2 million were estimated to be caused by multidrug-resistant
(MDR) strains of Mycobacterium tuberculosis (Mtb). MDR TB is
defined as TB caused by Mtb resistant to isoniazid and rifampin, two
of the four frontline TB drugs. MDR TB requires over 20 mo of
treatment with toxic second-line drugs (2). Extensively drug-resistant
(XDR) TB, which involves additional resistance to second-line drugs,
has been detected worldwide. A recent study with a 5-y follow-up of
patients with XDR TB in South Africa found that only 5% were
cured, 73% died, and 10% who failed treatment but survived were
discharged to the community with Mtb-positive sputum, that is, with
contagious XDR TB (3). There is an urgent need to deepen our
understanding of mechanisms of antimicrobial resistance (AMR).
Elucidation of AMR mechanisms will help in the development of
new anti-TB drugs. For example, a structural modification to a drug
candidate could avoid resistance, or combination therapy could in-
clude an inhibitor of an enzyme that inactivates the drug, as when
β-lactamase inhibitors are coadministered with β-lactams.
AMR in Mtb and other bacterial pathogens is heritable or phe-
notypic (4). Heritable AMR was observed in Mtb soon after the
use of the first TB drug, streptomycin, and led to the introduction
of combination chemotherapy to the practice of medicine (5).
Unlike many other bacterial pathogens, mycobacteria do not readily
exchange genetic material to spread resistance-causing genes; instead,
accumulation of spontaneous mutations allows selection for drug
resistance. Clinically, resistance to most frontline TB drugs is caused
by mutations in the activation pathways of prodrugs (e.g., katG
mutations can confer resistance to isoniazid) and/or mutations in
the target (e.g., rpoB mutations can confer resistance to rifampicin)
(6). Additional mechanisms of AMR have been described in Mtb
and the fast-growing Mycobacterium smegmatis (7). Some are non-
specific, such as increased expression of the efflux pumps Tap and
IniBAC (8, 9). Others involve direct modification and inactivation
of the drug, such as expression of the β-lactamase BlaC that hy-
drolyzes β-lactams (10) and the acetyl transferase Eis that acetylates
and inactivates kanamycin (11). Target modification plays a role in
macrolide resistance through methylation of 23S rRNA by the Erm
family of methyl transferases (12). However, to the best of our
knowledge, inactivation of an antibiotic by its methylation has not
been reported.
The goal of this study was to determine the mechanism of re-
sistance to and mode of action of 14 (Fig. 1A), which was recently
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identified as bactericidal to replicating Mtb (13). We identified the
mechanism of resistance as N-methylation of compound 14 by a
previously uncharacterized methyltransferase, Rv0560c. After the re-
sistance mechanism was incapacitated by genetic deletion of rv0560c,
selection of additional mutants at a far lower frequency allowed us to
identify the target of 14 as decaprenylphosphoryl-β-D-ribose 2-oxidase
(DprE1), an essential enzyme involved in arabinogalactan synthesis.
Results
Sterilizing Activity of 14 in Vitro. Earlier work showed that 14
inhibits Mtb growth with an IC90 of 0.39 μMand that the compound
is bactericidal under conditions that support bacterial replication
(13). In the present studies, we found that 14’s mycobactericidal
activity was dose- and time-dependent, with a multilog reduction in
colony-forming units observed at 0.78 μM after a brief exposure of 3
d and further colony-forming unit reduction to below the limit of
detection by 8 d (Fig. 1B). A recent study reported that some
antimycobacterial compounds with potent activity in vitro were in-
active in vivo because glycerol was used as the carbon source in the
in vitro experiments (14). However, we observed no change in the
IC90 of 14 when glycerol, dextrose, or acetate served as the carbon
source (SI Appendix, Fig. S1).
Resistance to 14 Is Associated with Mutations in rv2887. To elucidate
the mode of action of 14, we isolated resistant clones after in-
cubation of Mtb at 4-, 5-, 10-, or 20-fold the IC90 of 14 and
observed a frequency of resistance of 1–3 × 10−7 (SI Appendix,
Fig. S2A). Whole genome resequencing of four resistant clones
(highlighted in Table 1) found one gene, rv2887, to be mutated in
common. Rv2887 is annotated as a nonessential, putative tran-
scription factor. Amino acid sequence analysis predicted that
Rv2887 has the winged helix–turn–helix DNA binding domain
found in the MarR family of transcription factors (SI Appendix).
Mtb has at least six other genes that belong to this family,
namely, rv0042c, rv0737, rv0880, rv1049, rv1404, and rv2327.
These proteins share homology with MarR, the transcriptional
repressor of Escherichia coli linked to the multiple antibiotic
resistance (mar) phenotype. Resequencing of rv2887 in 16 ad-
ditional resistant clones revealed 12 additional SNPs leading to
missense or nonsense mutations (Table 1).
We used Phyre 2 (15) to build a homology model of Rv2887
that predicted an α1–α2–α3–α4–β1–loop–β2–α5–α6 topology, as
observed in crystal structures of E. coli MarR and its homologs
(Fig. 1C) (16). The N-terminal α1–α2 helices and C-terminal α5–α6
helices of a MarRmonomer interact with the corresponding regions
Fig. 1. Activity of 14 and the Rv2887 mutations identified in 14-resistant Mtb
clones. (A) Structure of 14. (B) Kinetics of bactericidal activity of 14 against
Mtb as measured by cfu counts on postexposure days 1, 3, 5, 8, and 15.
(C) Phyre 2 generated homology model of Rv2887 highlighting the 16 unique
mutations identified in Mtb clones resistant to 14. The secondary structure
elements are color coded as described: blue, α1 helix; light blue, α2 helix; light
green, α3 helix; dark green, α4 helix; orange, β1–loop–β2 region; dark red, α5
helix; and red, α6 helix. The dashed line demarcates the predicted dimer-
ization and DNA-binding domains.
Table 1. Characterization of Mtb clones resistant to 14
Strain name* IC90 of 14, μM SNP in rv2887 Mutation in Rv2887 Other SNPs
Fold change in
IC90 of RIF
WT 0.39 — — — —
1A 12.5 G242A R81Q Rv0516c:L69M, plcB:R190R,
3418802 A > G
1
2A 12.5 C274T P92S None in DprE1 0.5
5A 12.5 T122C L41P Rv0516c:L69M, plcB:R190R,
3418802 A > G
1
6A 25 G62A R21Q Rv1619:Y457H,
Rv2173/idsA2:S201P
1
8A >25 G400T C-term 6 AA deletion
and addition of 61 AA
Rv0560c:S140A 1
10A 25 G296T G99V None in DprE1 0.25
12A 12.5 C274T P92S None in DprE1 0.5
15A 12.5 G242A R81Q None in DprE1 0.5
17A 12.5 A191C Q64P — 1
183A 12.5 Insertion of 14 nts after G125
leading to stop codon after AA45
Stop codon after 45AA None in DprE1 1
183B 25 G263A G88E None in DprE1 1
183C 12.5 T59C L20P None in DprE1 1
189A 12.5 C176A A59E None in DprE1 1
195A 6.25 G119T C40F None in DprE1 1
195B 6.25 G170A R57Q None in DprE1 1
195C 6.25 G119T C40F None in DprE1 1
195D 6.25 T398C L133P None in DprE1 1
195E 6.25 G232C A78P None in DprE1 1
195F 6.25 C136T Stop codon after 45AA None in DprE1 1
195H 6.25 T398C L133P None in DprE1 1
*The names of strains analyzed by whole genome resequencing are in bold. RIF, rifampin.
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in a second monomer to form the functional dimer (16). Pre-
vious studies with E. coli mutant strains showed that point
mutations or deletions in the N or C termini of MarR led to loss
of repressor activity (17, 18). Nine of the 16 unique mutations
in our resistant clones mapped to the homologous regions of
Rv2887 (Fig. 1C and Table 1). The winged helix fold in MarR,
formed by the third and fourth helices and the β–loop–β sheet
domain, is predicted to bind the promoter region of the
marRAB operon in E. coli, and the remaining seven unique mu-
tations in our resistant clones mapped to the homologous domain
of Rv2887 (Fig. 1C and Table 1). Three of the mutated residues
identified in Rv2887—R81, G99, and Q64—are homologous to
MarR residues reported to be essential for DNA binding in E.
coli, where they correspond to R86, G104, and G69, respectively
(17, 19). R86 and G104 are among the most highly conserved
residues among MarR homologs across different species (16, 17,
19). Thus, each of the Rv2887 mutations identified in the re-
sistant clones is likely to cause complete or partial loss of the
DNA binding function of Rv2887.
Specific Role of Rv2887 in Mediating Resistance to 14. E. colimutants
lacking MarR and MarA are resistant to diverse antibiotics and
other stresses (20, 21). To determine if Rv2887 fulfilled a similar
role in Mtb, we tested susceptibility of two resistant clones, 1A
and 8A, to the TB drugs rifampin, isoniazid, ethambutol,
moxifloxacin, and streptomycin and did not observe increased
resistance or susceptibility relative to wild-type strain (SI Ap-
pendix, Fig. S2B). Replacement of the wild-type allele of rv2887
in Mtb with mutant allele carrying the point mutations found in
these two resistant clones, namely R81Q (as found in clone 1A)
or deletion of six amino acids at the C terminus (as found in
clone 8A), by oligonucleotide-mediated recombineering (22),
conferred resistance specifically to 14 (Fig. 2A and SI Appendix,
Fig. S2C). However, introduction of the rv2887 mutation found
in resistant clone 8A into wild-type Mtb did not lead to a level of
resistance as high as that displayed by clone 8A itself (IC90 > 25
μM). This data suggested that additional mutations in clone 8A
might contribute to its high level of resistance. Whole genome
resequencing of clone 8A revealed an additional SNP leading to
S140A mutation in Rv0560c, whose significance emerged in
studies described below. To confirm the role of Rv2887 in re-
sistance to 14, wild-type rv2887 was overexpressed in the resistant
clones 1A and 8A. Overexpression of rv2887 increased the sus-
ceptibility of both clones to 14 (Fig. 2A).
Genes and Pathways Regulated by Rv2887. Based on similarity of
Rv2887 to the transcriptional repressor MarR, we hypothesized
that loss-of-function mutations in Rv2887 lead to derepression
of the target of 14 or of genes linked to the target pathway.
RNAseq gene expression profiles of the wild-type strain and the
resistant clones 1A and 8A were generated after 4 h of exposure
to 14 or vehicle (DMSO). In the absence of compound treat-
ment, resistant clones 1A and 8A had a common set of 13 up-
regulated genes and 17 down-regulated genes, relative to the
wild-type strain (SI Appendix, Table S1). The gene with the
largest increase in expression—∼400-fold—was rv0560c, anno-
tated as a putative, nonessential benzoquinone methyltransferase.
The gene rv0559c, which is predicted to be in the same operon as
rv0560c, was up-regulated by ∼15-fold in vehicle-treated resistant
clones. Two genes transcribed in the opposite direction from the
rv0560c operon, rv0557 and rv0558, were also up-regulated in the
resistant clones, by ∼threefold and ∼20-fold, respectively. Unlike
E. coli marR, which is self-regulated, rv2887 expression was not
altered in the resistant clones. The down-regulated genes in-
cluded the tRNA and noncoding RNA transcripts asnT, argV,
and mpr11 (SI Appendix, Table S1), but no protein-coding
transcripts.
The RNAseq results thus directed our attention to the cluster
of four protein-coding genes up-regulated in the rv2887 mutants,
rv0557–rv0560c. Quantitative reverse transcriptase (qRT) PCR
(Fig. 2B) confirmed that rv0560c, rv0559c, and rv0558 were sig-
nificantly up-regulated (>fivefold) in the resistant clones, whereas
rv0557 was not. Finally, rv0560c was found to be up-regulated by
∼eightfold and ∼40-fold as detected by qRT-PCR (Fig. 2B) and
RNA Seq (SI Appendix, Table S1), respectively, in wild-type Mtb
exposed to 3.9 μM (∼10× IC90) of 14 for 4 h. In contrast, ex-
posure of wild-type Mtb to 14 did not affect expression of
rv0559c and rv0558. Based on these data, we predicted a model
in which Rv2887 acts as a repressor of rv0560c and loss-of-
function mutations in Rv2887 lead to derepression and thus in-
creased expression of rv0560c.
Rv2887 Binds to the Promoter Region of rv0560c. Previous charac-
terization of the promoter region of rv0560c identified the pu-
tative −35 and −10 elements and predicted a putative repressor
binding site (23). We determined if recombinant Rv2887 (SI
Appendix, Fig. S3A) could bind the 70-bp region spanning the
reported promoter region of rv0560c (560c-prom) (SI Appendix,
Table S2). Migration of the oligonucleotide in the gel was re-
tarded by ≥1 molar equivalent of Rv2887 (Fig. 2C). Quantitative
analysis of band intensities indicated 50% reduction in the un-
bound DNA at 1.5 molar equivalent of Rv2887 (SI Appendix, Fig.
S4). Rv2887 did not bind to a 36-bp region corresponding to the
promoter region of an IdeR-regulated gene, mbtB (mbtB-prom)
(SI Appendix, Fig. S4) (24). Our observation that Rv2887 regulates
Fig. 2. Role of rv2887 in resistance to 14 and genes regulated by Rv2887 in
Mtb. (A) Fold changes in IC90 of 14 relative to wild-type Mtb H37Rv (WT) are
shown. The strains tested are two clones resistant to 14, 1A and 8A; wild-
type strains carrying the two Rv2887 mutations, R81Q and C-terminal de-
letion, found in clones 1A and 8A; and three strains, WT, 1A, and 8A, that
express rv2887 constitutively (WT o/e rv2887, 1A o/e rv2887, and 8A o/e
rv2887). o/e, overexpression. (B) Relative change in expression of rv0560c,
rv0559c, rv0558, and rv0557 in wild-type Mtb H37Rv (WT) treated with
3.9 μM of 14 for 4 h and two resistant clones, 1A and 8A, that were vehicle-
treated for 4 h. The baseline of 1 indicates expression level in Mtb H37Rv
treated with vehicle control. (C) Native PAGE gels of wild-type Rv2887 or
mutant Rv2887, with the point mutation R81Q, incubated with a 70-bp DNA
sequence spanning the promoter of rv0560c (560c-prom).
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expression of Rv0560c is supported by a recent genome-wide
analysis of regulatory interactions in Mtb using ChIP-Seq- and
RNA-Seq-based assays (25). Introduction of the R81Q mutation
into Rv2887 abolished its ability to bind 560c-prom DNA (Fig.
2C and SI Appendix, Fig. S4), providing direct evidence that the
mutation present in resistant clone 1A impacts ability of Rv2887
to bind the promoter region of rv0560c. We also examined the
impact of mutations in 560c-prom DNA sequence, both those in
palindromic regions and those previously reported to affect re-
pression (23), on binding by Rv2887 in vitro, and observed a mild
effect at ≥2 molar equivalents of Rv2887 (SI Appendix, Fig. S4).
Rv0560c Methylates and Inactivates 14. We hypothesized that up-
regulation of rv0560c, rv0558, or rv0559c could be contributing to
the resistance phenotype of the clones, 1A and 8A. We tested
susceptibility of wild-type Mtb individually overexpressing each
of these genes to 14. Mtb became 16-fold more resistant to 14
when rv0560c was overexpressed, whereas overexpression of
rv0558 and rv0559c had no impact on sensitivity to 14 (Fig. 3A
and SI Appendix, Fig. S5). Because Rv0560c is reportedly non-
essential (26), we reasoned that it was unlikely to be the target of
14. Instead, given that increased expression of Rv0560c con-
ferred resistance to 14 on the wild-type strain, we hypothesized
that Rv0560c inactivates 14, directly or indirectly. Moreover,
given that the most resistant mutant was clone 8A, which carried
mutations in both rv2887 and rv0560c, we predicted that the S140A
mutation in Rv0560c might augment the ability of Rv0560c to
inactivate 14.
Based on the putative methyltransferase activity of Rv0560c,
we tested recombinant Rv0560c and S140A-Rv0560c (SI Ap-
pendix, Fig. S3B) for methyltransferase activity with 14 as the
candidate substrate. After overnight coincubation of 14 with
S-adenosyl-L-methionine (SAM) and Rv0560c, mass spectrometry
coupled to liquid chromatography (LC-MS) analysis detected an
additional peak with an m/z of 363.18, which is 14 mass units
(CH2 group) greater than that of 14 (SI Appendix, Fig. S6). We
then examined the kinetics of methylation of 14 by Rv0560c and
S140A-Rv0560c by taking advantage of the characteristic blue
shift at 380 nm observed in the absorption spectrum of 14 upon
methylation (SI Appendix, Fig. S7A). Initial velocity of the
methylation reaction, as reflected by the absorbance changes at
380 nm, depended on the concentration of Rv0560c (SI Appen-
dix, Fig. S7B). Although wild-type Rv0560c can modify 14, the
substrate turnover measured by kcat was increased by 2.4-fold for
S140A-Rv0560c (Fig. 3B). Enhancement was even greater when
S-adenosyl-L-homocysteine (SAH) was depleted by two coupled
enzymes, 5′-methylthioadenosine/S-adenosylhomocysteine nucle-
osidase (MTAN) and adenine deaminase (SI Appendix, Fig. S7C).
SAH, the common byproduct of methylation, is often character-
ized as a pan-inhibitor of methyltransferases and can be rapidly
degraded inside cells by other metabolic enzymes, as mimicked by
the addition of the coupling enzymes mentioned above (27). Given
that S140 is predicted to be near to a putative SAM binding site, the
increased methyltransferase activity of S140A-Rv0560c relative
to wild-type Rv0560c may be attributed to increased kcat/Km, de-
creased SAH inhibition, or a combination of both.
We then sought to determine the site of methylation on 14
using NMR. Comparison of 1H-NMR spectra of 14 and its
methylation product, me-14, revealed the nascent methyl group
at 4.1 ppm (Fig. 3C). The 1H–1H COSY [number of scans (ns) = 8]
allowed us to assign all of the peaks in 1H spectra of 14. A gradient
NOESY experiment was set up with the optimal mixing time of 0.8
s for the characteristic methyl group of me-14 (ns = 32). An NOE
cross-peak between 4.1 ppm and the doublet around 7.3 ppm (C-6
proton) indicated that N-5 is the site of methylation (Fig. 3C).
Similar assays were conducted with an analog of 14, 14-IA (SI
Appendix, Fig. S8), which has a methyl group at N-5 and was in-
active against Mtb (Fig. 3D). As expected, a characteristic NOE
cross-peak was observed between the C-6 doublet of the analog
14-IA at 7.3 ppm and the N-5 methyl proton at 4.1 ppm (SI
Appendix, Fig. S8). We conclude that Rv0560c is an N-methyl-
transferase that modifies 14 at the N-5 position.
We used Rv0560c to generate me-14 in vitro, extracted it from
the reaction mixture, and tested it against wild-type Mtb. Like
the synthetically prepared analog 14-IA, me-14 did not inhibit
growth of Mtb (Fig. 3D), confirming that resistance to 14 can
arise by its inactivation upon N-methylation by Rv0560c.
Fig. 3. Role of Rv0560c in resistance of Mtb toward 14. (A) IC90 curve of
14 and rifampin (RIF) against wild-type Mtb strain that constitutively ex-
presses rv0560c (pMV261-rv0560c) or the vector control strain (pMV261).
(B) Michaelis–Menten kinetics of the SAM-dependent methylation of 14 by
wild-type Rv0560c (WT) protein and S140A-Rv0560c protein in the absence
of coupling enzymes. Table lists the steady-state kinetic parameters of the
reactions. (C) Overlay of the 1D 1H spectrum and the NOESY spectra of me-
14 with a schematic highlighting the site of methylation. (D) Activity of
purified methylated 14 (me-14), 14, and the inactive analog, 14-IA, which is
methylated at the N-5 position. (E ) Normalized (relative to wild-type Mtb
H37Rv, Rv) quantification of 14 and me-14 in the two 14-resistant clones,
1A and 8A, in the wild-type strain that constitutively expresses rv0560c (Rv
O/E rv0560c), in Δrv0560c, its wild-type background strain, H37Rv London
Pride (LP), and Δrv0560c complemented with a constitutive expression
vector for rv0560c (Δrv0560c O/E rv0560c). All strains were treated with
7.8 μM 14 for 24 h. (*P < 0.05; **P value < 0.01, with two-tailed unpaired
t test analysis.)
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Methylation Reduces the Level of 14 in Resistant Clones. We next
sought to relate the foregoing in vitro observations to the mech-
anism of resistance within mutant Mtb. To do this, we treated
bacteria with 7.8 μM (∼20× IC90) of 14 for 24 h and measured
intrabacterial levels of 14 and me-14 in resistant clones and in
wild-type Mtb overexpressing rv0560c. There was no significant
increase in the amount of me-14 in the resistant clones relative to
the wild-type strain (H37Rv North strain, Rv), either inside the
bacteria or in the extracellular medium (Fig. 3E and SI Appendix,
Fig. S9). However, the amount of parent compound, 14, was re-
duced by fivefold in the resistant clones and by twofold in the
rv0560c-overexpressing strain (Fig. 3E). The unchanged levels of
me-14 in these cells might be due to the brief exposure to a large
excess of 14. Moreover, these observations raise the possibility
that me-14 may be subject to further modifications in Mtb. In
contrast, levels of me-14 in a Δrv0560c strain were 20-fold lower
than in the wild-type control strain (H37Rv London Pride strain,
LP), accompanied by a ∼10-fold increase in 14 (Fig. 3E). Both
differences were reversed by constitutive expression of rv0560c in
the knockout strain (Fig. 3E). Collectively, these studies estab-
lished that Rv0560c catalyzes the methylation of 14 within Mtb.
DprE1 Mutations Confer Resistance to 14 in the Absence of Rv0560c.
To circumvent selection of resistant clones carrying rv2887 or
rv0560c mutations, we isolated resistant clones in the Δrv0560c
background. The observed frequency of resistance to 14 in
Δrv0560c strain was 100-fold lower than for wild-type Mtb and
ranged between 0.5 × 10−9 and 8.5 × 10−9 (SI Appendix, Fig.
S10A). Three of the four analyzed clones carried a point muta-
tion, P116S, in dprE1, an essential gene involved in synthesis of
decaprenylphosphoryl-β-D- arabinose (DPA) (SI Appendix, Fig.
S10B). Introduction of this mutation into wild-type Mtb by
replacing the wild-type allele with oligonucleotide-mediated
recombineering led to a 16-fold increase in IC90 (Fig. 4A). These
data indicated that DprE1 could be the main target of 14, and
this possibility was tested as described in Inhibition of DprE1 by
14. Whole genome resequencing of four clones identified com-
mon mutations in rv0678, the putative regulator of the MmpL5-
S5 transporter system, in all four clones (SI Appendix, Fig. S10B)
(28). Hence, increased efflux of 14 through MmpL5 might occur
in these resistant clones in addition to reduced inhibition of
DprE1.
Inhibition of DprE1 by 14.Using a previously reported fluorescence-
based assay (29) to monitor inhibition of pure, recombinant Mtb
DprE1 by 14, we observed an IC50 of 70 nM against DprE1 (Fig.
4B). Preincubation of 14 with Rv0560c in the presence of SAM
led to a 36-fold increase in the IC50 (Fig. 4B). Thus, 14 is a potent
inhibitor of DprE1, and methylation by Rv0560c markedly re-
duced this activity. Based on the proximity of the P116 residue to
the flavin adenine dinucleotide (FAD) cofactor-binding site in
DprE1, we hypothesized that displacement of FAD by 14 might be
the mechanism of its DprE1 inhibition. We monitored release of
FAD in the presence of 14, but no release was detected (SI Ap-
pendix, Fig. S11A). A 20-fold increase in FAD fluorescence would
have been observed if there was release (29); instead, binding of
14 to DprE1 caused a slight quench in FAD fluorescence (SI
Appendix, Fig. S11A). We analyzed DprE1 by mass spectrometry
after incubation with 14 and the substrate farnesylphosphoryl-β-D-
ribose (FPR) to monitor the formation of covalent adducts by the
inhibitor, but none were detected (SI Appendix, Fig. S11B). This
data is also consistent with the inhibition assay data, which showed
no evidence of time-dependent inhibition.
Recent studies have described six mutations in DprE1, namely
C387S (30), Y314H (31), L368P (32), G17C (32), E221Q (29),
and G248S (29), associated with resistance to inhibition of the
enzyme by diverse molecular scaffolds. We interrogated the roles
of these residues in the interaction of 14 with DprE1 by measuring
the IC90 of 14 against Mtb strains carrying these point mutations
(Fig. 4C). The greatest resistance to 14 (∼16- to 32-fold increase
in IC90) was seen in the strains in which either P116 or E221 were
mutated. A milder effect (∼sixfold to eightfold increase in IC90)
was observed when L368 or G248 were mutated. The covalent
inhibitor BTZ043 was inactive only when C387, the key residue
with which it forms a covalent bond with DprE1, was mutated.
The activity of TCA1 was dramatically reduced when Y314 or
P116 were mutated. None of these mutations affected the activity
of ethambutol, isoniazid, and rifampin. Finally, overexpression of
DprE1 conferred resistance to 14, as it did to the DprE1 inhibitors
TCA1 and BTZ043 (Fig. 4C).
Discussion
We have uncoveredN-methylation of antimicrobial compounds as a
novel mechanism of AMR. Mtb exploits this mechanism to counter
the antimycobacterial action of a potent pyrido-benzimidazole, 14,
with bactericidal activity against replicating Mtb. The nonessential
gene rv0560c, annotated as a putative benzoquinone methyltrans-
ferase, was found to inactivate 14 by catalyzing the transfer of a
methyl group from SAM to the N-5 position. Mtb clones resistant to
14 up-regulated expression of rv0560c by incurring mutations in the
transcriptional repressor, Rv2887. Winglee et al. (33) recently
reported a role for Rv2887 in Mtb’s resistance to imidazo[1,2-a]
pyridine-4-carbonitrile (MP-III-71), a compound with structural
similarity to 14. That study also documented up-regulation of
rv0560c in the setting of resistance-conferring mutations in rv2887,
but did not directly implicate Rv0560c in resistance nor establish a
biochemical mechanism for mycobacterial resistance to MP-III-71.
Methylation now joins a list of covalent modifications of an-
tibacterial compounds by which bacteria can manifest AMR,
Fig. 4. Compound 14 targets Mtb DprE1. (A) IC90 curve of 14 against two
resistant clones, R Clone 1 and 2, isolated in the Δrv0560c background, which
is referred to as WT-rv0560c KO. Activity against the recombineered H37Rv
strain carrying only the DprE1 P116S point mutation (P116S DprE1) and its
wild-type control strain (WT-reco) are also shown. (B) Concentration-
dependent activity of 14 against DprE1 as detected by a fluorescence-based
assay is depicted by grey symbols. Activity of 14 against DprE1 after pre-
incubation with 10 μM Rv0560c and 300 μM SAM for 6.5 h is depicted by
clear symbols, and the control without SAM is shown by black symbols.
(C) Activity of 14, the known DprE1 inhibitors TCA1 and BTZ-043, etham-
butol (EMB), rifampin (RIF), and isoniazid (INH) against Mtb H37Rv strains
carrying the listed point mutations in DprE1. Mutations highlighted in red
were introduced into the wild-type Mtb strain by oligonucleotide-based
recombineering.
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including acetylation, phosphorylation, adenylation, and hydro-
lysis (34). Previous studies have shown that some proportion of
intrabacterial para-amino salicylic acid (PAS) is methylated in
PAS-sensitive Mtb treated with PAS (35). However, methylation
of PAS by Mtb has not been observed to cause PAS resistance
(36). Bacterial methyltransferases of the Erm family contribute
to AMR by modifying the target of macrolides, rRNA, but those
methyltransferases do not act on the macrolides themselves.
Rv0560c-mediated inactivation of 14 is, to our knowledge, the
first instance of compound methylation as a resistance mecha-
nism in a bacterial species.
It is unclear how Mtb senses 14 such that a consequence is the
relief of repression of rv0560c. One hypothesis is that 14 directly
binds to Rv2887. Alternatively, an endogenous metabolite as-
sociated with DprE1 inhibition may accumulate as a conse-
quence of its inhibition and bind to Rv2887, initiating a response
to the stress of cell wall synthesis blockade. Diverse stresses,
including salicylate, membrane depolarizers (carbonyl cyanide
m-chlorophenyl hydrazone, valinomycin, or dinitrophenol), the
detergent SDS, and the respiratory inhibitors chlorpromazine
and thioridazine, can up-regulate rv0560c expression (www.tbdb.
org/expressionHistory.shtml?gn=Rv0560c). We hypothesize that
this occurs by the dissociation of Rv2887, the repressor, from the
rv0560c promoter region. This theory is corroborated by the very
low number of rv0560c transcripts in untreated, wild-type Mtb
(SI Appendix, Table S1), compared with the marked up-regulation
of rv0560c in Mtb strains carrying mutations in Rv2887 (Fig. 2B)
and demonstration of a direct interaction of Rv2887 with the
promoter region of rv0560c in a mobility shift assay (Fig. 2C).
Although PAS, chlorpromazine, and thioridazine have been
reported to up-regulate rv0560c gene expression, we did not
observe increased resistance to these compounds in the clones
1A and 8A, which have markedly higher rv0560c transcripts (SI
Appendix, Fig. S12). It is unclear how Rv0560c, a putative cyto-
plasmic enzyme, inactivates 14 before 14 targets DprE1, whose
activity has been localized to the Mtb cell wall (37). There may
be an uptake mechanism for 14 that delivers most of it from the
extracellular medium to the cytosol before it can reach DprE1 in
the periplasm, or perhaps marked increase in expression of Rv0560c
results in some of the enzyme becoming periplasmic.
Two other MarR homologs in Mtb, Rv1049 (MosR) and
Rv1404, have been shown to respond to physiologically relevant
stresses. For example, exposure to hydrogen peroxide or nitric
oxide led to dissociation of MosR from DNA and subsequent up-
regulation of the putative oxidoreductase Rv1050 (38). Rv1404
was involved in Mtb’s response to acid and hypoxia by up-reg-
ulating 10 genes, including two putative methyl transferases,
Rv1403c and Rv1405c (39).
The P116S mutation in DprE1 that we found to confer re-
sistance to 14 is different from the mutations that confer re-
sistance to several other DprE1 inhibitors. Covalent inhibitors of
DprE1 exemplified by BTZ043 select for the C387S substitution
in DprE1 because they require Cys-387 to form adducts. TCA1
requires Tyr-314 for its inhibition of DprE1. Compound 14 was
active against Mtb clones carrying both the C387S and Y314H
mutations, indicating that its interaction with DprE1 occurs by a
mechanism distinct from that of BTZ043 and TCA1. In contrast,
14 selects for the P116S mutation in DprE1. Pro-116 is adjacent
to the FAD binding pocket in the DprE1 active site. Compound
14 is predicted to be largely planar, similar to the isoalloxazine
ring system of the FAD. Although 14 did not displace FAD from
the enzyme, it might engage in a π-stacking interaction with the
FAD in the substrate-binding site, thus inhibiting enzymatic
turnover by competing with the substrate.
In conclusion, our analysis of Mtb’s resistance mechanism to
the inhibitor, 14, revealed that a bactericidal compound could be
inactivated by methylation. To the best of our knowledge, this is
the first report of N-methylation as a strategy for bacterial drug
resistance. The target of 14 is DprE1, the essential oxidoreduc-
tase involved in DPA synthesis, leading to inhibition of cell wall
synthesis and death of mycobacteria. Knowledge of the resistance
mechanism provides a mechanistic rationale to overcome resistance
to this class of antimycobacterial agents. We established that the
mycobacterial enzyme catalyzing this reaction, Rv0560c, can serve
as an N-methyl transferase. It remains for further study to identify
the physiologic roles of Rv2887 and Rv0560c in Mtb not exposed
to xenobiotics.
Methods
Materials.Mtb strains were grown in Difco Middlebrook 7H9 (BD Biosciences)
medium with 0.2% glycerol, 10% (vol/vol) OADC (BD Biosciences) or ADN
(0.5% BSA; Roche, 0.2% dextrose, 0.085% NaCl) and 0.02% tyloxapol, or
plated on 7H11 agar (BD Biosciences) supplemented with 10% (vol/vol)
OADC (BD Biosciences) and 0.5% glycerol; 7H10 agar (BD Biosciences) sup-
plemented with 10% (vol/vol) ADN and 0.5% glycerol was used to grow Mtb
strains on PVDF filters (Durapore) to quantify intrabacterial abundance of
14. Mtb H37Rv North strain (Rv) was used as the wild-type strain, unless
otherwise specified. The strain deficient in rv0560c (Δrv0560c) and its wild-
type background strain, H37Rv London Pride (LP), were a kind gift from
Tanya Parish, Infectious Disease Research Institute, Seattle, and the strains
carrying the point mutations C387S (30), L368P, and G17C (32) in DprE1 were
a kind gift from Stewart Cole, École Polytechnique Fédérale de Lausanne,
Lausanne, Switzerland. Compound 14 was provided by GSK or purchased
from Vitas Lab (Cat#STK717481). Compound 14-IA was provided by GSK.
Rifampin, isoniazid, TCA1 (Life Chemicals), and BTZ-043 (Selleckchem) were
obtained from commercial vendors. MTAN was purified as described (40),
and adenine deaminase was purchased from G-Biosciences. All other re-
agents were purchased from Sigma-Aldrich unless otherwise specified.
IC90 and Colony-Forming Unit Assays.Mtb strains were grown to log phase and
diluted to an optical density (OD580) of 0.005 in 7H9 medium. Then 200 μL/well
of the Mtb suspension was dispensed in 96-well plates (Costar), and com-
pounds were added. OD580 was read after 10–14 d of incubation at 37 °C
with 20% O2, 5% CO2. IC90 was defined as the concentration that led to
≥90% growth inhibition. The Resazurin Microtiter Assay was used to mea-
sure IC90 of compounds against strains carrying the Y314H, E221Q, G248S,
C387S, L368P, and G17C mutations in DprE1, as described (41). Colony-
forming unit assays were set up after exposure of a single-cell suspension of
Mtb in 7H9 medium at an OD580 of 0.005 to various concentrations of 14. At
each time point, the samples were mixed, diluted 10-fold in PBS with
tyloxapol (0.02%), and spread on 7H11 agar plates. Plates were incubated at
37 °C for 21–25 d, and colonies were counted.
Generation of Constructs for Constitutive Expression of Genes in Mtb and for
Expression and Purification Proteins from E. coli.Details of the cloning strategy
and the primers used for cloning are included in SI Appendix.
Isolation of Mtb Clones Resistant to 14 and Whole Genome Sequencing. Log
phase culture of Mtb H37Rv, LP, or Δrv0560c strains were plated on 7H11
agar with 4-, 5-, 10-, or 20-fold the IC90 of 14. Colonies visible after 3–5 wk
were counted to measure frequency of resistance. These colonies were
subjected to a second round of selection and then grown up in 7H9 medium
with the corresponding concentration of 14 as a selection pressure. DNA was
extracted using cetyltrimethylammonium bromide and lysozyme as de-
scribed (42). The genomes of the resistant mutants characterized in this
study were sequenced using an Illumina HiSeq 2500. The read length was
between 54 bp and 125 bp (depending on sequencing run), and paired-end
data were collected. Genome sequences were assembled by a comparative
assembly method using custom-developed scripts for mapping reads and
building contigs to identify indels, as described (43). Previously sequenced
genomes of the parental strain (local stocks of Mtb H37Rv) for each of the
mutants were used as reference sequences for the comparative assembly
and for calling SNPs and other polymorphisms. Targeted sequencing
(Macrogen Corp.) of dpre1 and rv2887 was performed after PCR amplifica-
tion of the genes using the primers listed in SI Appendix, Table S2.
Transfer of SNPs Encoding Resistance to 14 into Wild-Type Mtb. Transfer of the
SNPs encoding the R81Q and C-terminal deletion mutations in Rv2887 and the
P116S, E221Q, G248S, and Y314H mutations in DprE1 into wild-type Mtb was
performed by oligonucleotide-mediated recombineering as described (22),
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using the oligonucleotides listed in SI Appendix, Table S2. Details of the
method are included in SI Appendix.
RNASeq and qRT-PCR. Log-phase culture of Mtb H37Rv-North (Rv) and the
clones resistant to 14, 1A and 8A, were treated with 3.9 μM of 14 or with
vehicle control (1% DMSO) for 4 h. RNA was extracted and the mRNA was
enriched using the MicrobExpress kit (Ambion). The cDNA libraries were
synthesized according to instructions of the TruSeq RNA kit (LS protocol;
Illumina), and RNA sequencing was performed with HiSeq2000/1000
(Illumina). The sequenced reads were aligned to the Mtb H37Rv com-
plete genome (National Center for Biotechnology Information database)
using Burrows–Wheeler alignment tool (44). The transcript abundances were
measured in reads per kilobase of exon per million mapped reads (RPKM)
using the Cufflinks package (45). Up- or down-regulated genes were iden-
tified based on the criteria that expression levels differed by >twofold rel-
ative to control and RPKM > 10 in all samples. Data are available at the GEO
database (accession no. GSE77556). Reverse transcriptase (qScript cDNA
synthesis kit from Quanta Biosciences)-generated cDNA was used for PCR
amplification (PerfectA qPCR FastMix UNG from Quanta Biosciences) and
quantification of rv0560c, rv0559c, rv0558, rv0557, and rv2887 expression
levels with sigA expression as the normalization control for cDNA input.
Primer and probe sequences are listed in SI Appendix, Table S2.
EMSA Assay. Purified Rv2887 (wild type or R81Q) was incubated with 50 nM of
a 70-mer spanning the promoter region of rv0560c (wild type or mutant;
SI Appendix, Table S2) or 36-mer spanning mbtB promoter in binding buffer
(pH 8) with 20 mM Tris·HCl, 50 mM KCl, 5 mM MgCl2, 0.25 mg/mL BSA, and
10% glycerol for 10 min at room temperature. The samples were run in a
12% nondenaturing Tris-borate-EDTA (TBE) buffered gel for 1.75 h at 110V
in 1× TBE buffer on ice. The gels were stained with a 1:10,000 dilution of
SYBR Gold nucleic acid stain (Life Technologies) in 1× TBE buffer for 10 min
at room temperature. Before loading the samples, the gel was prerun at 100
V for 30 min on ice. DNA bands were visualized with UV light using the
Genius Bioimaging system (Syngene), and images were captured. ImageJ
was used to quantify the intensity of the DNA bands (area under the peaks
formed by bands). Values were normalized to control samples without
Rv2887 protein and plotted against the protein/DNA ratio.
Methylation of 14 by Rv0560c. Initially, methylation of 14 by wild-type Rv0560c
and S140A-Rv0560c wasmonitored using a coupled spectrophotometric assay
as described (27). However, because of overlap in the absorption spectra of
14, the initial velocities could not be measured at 260 nm. Instead, the re-
action was monitored at 380 nm due to the blue shift in the absorption
spectra of 14 upon methylation. Upon confirmation of a dependence of the
monitored initial velocity on the enzyme concentration, steady-state kinetic
analysis of wild-type Rv0560c and S140A-Rv0560c was performed in a 96-
well plate format using a SpectraMax M2 microplate reader. For SAM de-
pendence, 25 μM 14, 25 nM MTAN, and 2 nM adenine deaminase were
allowed to equilibrate at 37 °C in 10 mM phosphate buffer saline (2.7 mM
KCl, 138 mM NaCl) with 10 mM MgCl2, pH 7.4. The reaction was initiated by
adding 670 nM wild-type enzyme or 600 nM S140A-Rv0560c. For substrate
dependence, 96 μM SAM was used in the reaction mixture. The initial ve-
locity was converted to units of concentration using an extinction coefficient
(«380nM) of 13,200 M
−1·cm−1 for 14. The initial velocities were calculated and
plotted using Prism. The kinetic parameters were also tested in the absence
of the coupling enzymes using the same setup.
NMR-Based Determination of Methylation Site in 14. The methylation reaction
was set up on a 15-mL scale with 25 μM 14, 96.5 μM SAM, 0.6 μM S140A-
Rv0560c, 25 nMMTAN, and 2 nM adenine deaminase at 37 °C for about 15 h.
The formation of the product was confirmed using LC-MS (363 m/z [M+H]+).
The methylated product was extracted using chloroform and purified using
reverse phase column chromatography (XBridge prep C18, 5 μm) with a
5–95% gradient of acetonitrile/water with 0.1% TFA (flow rate 10 mL/min;
retention time 12.2 min). The product was lyophilized and dissolved in
500 μL CDCl3 for identifying the site of methylation using NMR spectroscopy.
All NMR spectra were acquired on a 600-MHz Brüker AVIII. A 1H-1H COSY
(ns = 8) experiment was used to assign the 1H spectra of 14 and 14-IA along
with literature mining to confirm assignment of C-6 and C-9 protons of 14
and 14-IA. The gradient NOESY experiments for both 14 and 14-IA were
performed with a mixing time of 0.8 s (ns = 32).
Quantification of Intrabacterial Amounts of 14 and me-14. H37Rv wild-type
strain (Rv), Rv strain constitutively expressing rv0560c, resistant clones, 1A
and 8A, H37Rv London Pride (LP), and Δrv0560c strains were grown to log
phase and inoculated on filters at a density of 3.5–5 × 108 bacteria per
milliliter. The filters were transferred onto 7H10 agar plates and incubated
at 37 °C for 5–7 d to allow bacterial growth. The filters were then exposed to
7.8 μM of 14 in 7H9 medium (without tyloxapol) for 24 h, and the metab-
olites were extracted with a mixture of acetonitrile:methanol:water
(40:40:20) as described (46). The extracellular medium was also collected for
analysis. LC-MS (46) was used to detect 14 (m/z of 349.16 in the positive
mode) and me-14 (m/z of 363.18 in the positive mode) in the lysates and
extracellular medium. BCA assay (Thermo Scientific) was used to measure
protein amounts in the samples to normalize to sample biomass.
Enzyme Assay for DprE1. Compounds were dispensed in a black 384-well low-
volumemicroplate (Greiner Bio-One) using a Hewlett Packard HP D300 digital
dispenser (Tecan Group Ltd.). Preincubation mix (5 μL) containing 10 μM
Rv0560c and 300 μM SAM in assay buffer (50 mM Hepes, pH 7.5, 100 mM
NaCl, 100 μM Tween-20, 2 μM FAD, and 4 μM BSA) was added, and the re-
actions were incubated for 6.5 h at 25 °C to allow covalent modification of
compounds. Substrate mix (5 μL) containing 1 mM FPR and 50 μM resazurin in
assay buffer was then added (both are final assay concentrations). The DprE1
reactions were initiated immediately by adding enzyme mix (5 μL) containing
50 nM DprE1 in assay buffer and monitored spectrofluorimetrically using a
Tecan Safire2 instrument (Tecan Group Ltd.). The DprE1 enzyme assay and
data analysis have been described in detail (29).
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